Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IBI3003 · 1 trial · 1 indication
Number of patients who Experienced related AEs from the first dose until 30 days after the last dose
To evaluate the safety and tolerability of IBI3003
To evaluate the preliminary efficacy of IBI3003 in the specified participant population.
| Arm | Type | Description |
|---|---|---|
| IBI3003 | EXPERIMENTAL | Participants will receive IBI3003 treatment until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, or end of the study or for a maximum of 24 months, whichever occurs first. |
| Name | Type | Description |
|---|---|---|
| IBI3003 | DRUG | Participants will receive IBI3003 treatment until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, or end of the study or for a maximum of 24 months, whichever occurs first. |
Inclusion Criteria Participants in Parts 1 \& 2 must satisfy all of the following criteria to be enrolled in the study: 1. Age ≥18 years. 2. Documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria. Multiple myeloma is defined as clonal bone marrow plasma cells ≥1...
Top 20 of 25 competitors
IBI3003 is an investigational small molecule being developed for the treatment of multiple myeloma. It is currently in Phase 1 clinical development for patients with relapsed or refractory multiple myeloma. The drug is being studied in a single-arm, open-label trial to evaluate its safety and efficacy in this patient population.
IBI3003 is being developed by BrainsWay Ltd., a biopharmaceutical company traded on the stock exchange under the ticker symbol BWAY. The company is conducting a Phase 1 clinical trial to evaluate the drug in patients with relapsed or refractory multiple myeloma.
IBI3003 is currently in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 1 trial is designed to assess the safety, tolerability, and preliminary efficacy of IBI3003 in patients with relapsed or refractory multiple myeloma.
IBI3003 is being evaluated in a Phase 1 clinical trial with the identifier NCT07336472. This study is titled 'A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma' and is currently not yet recruiting participants. The trial plans to enroll approximately 360 patients aged 18 years and older.
IBI3003 is a small molecule being developed for multiple myeloma. The clinical trial for IBI3003 includes biomarker selection, indicating that the study may involve patients whose tumors express specific biomarkers. However, the specific molecular target of IBI3003 has not been disclosed in the available information.